Posted 10th January 2022 by Nicholas Noakes
It was clear that microbiome companies have been advancing their programs as rapidly as ever, despite the changes brought about by the global pandemic. Service providers—including drug manufacturing organizations—have been busy during the past year, as they continue actively helping diagnostics and therapeutics companies find solutions to advance their products.
Posted 9th December 2019 by Joshua Sewell
Some of the claims made about Probiotics can be hard to believe, and often even harder to reliably prove. However, the science surrounding the development of these products is exciting, and some of the more extraordinary claims can be quantified.
Here a few examples from some of the presentations at the Microbiome & Prebiotics Series: USA:
Posted 2nd December 2019 by Joshua Sewell
I am extremely sceptical of all claims about probiotics. For the last 10 years of running Probiotics.org, companies have been sending me questionable products with extraordinarily impossible to believe claims.
But, after Global Engage’s 4th Probiotic & Prebiotics Congress, here’s what I strongly believe:
Posted 14th October 2019 by Jane Williams
Presented at this year’s Microbiome Series: Europe, these poster presentations are now available to download and share with your colleagues.
Posted 23rd August 2019 by Jane Williams
The Microbiome & Probiotics Series: Europe is one of the highlights of our calendar year. Kristin Neumann, author & founder of MyMicrobiome was one of our speakers on the cosmeceuticals track and was kind enough to write the following recap of the event, for people who weren’t able to attend this year. You can read the original article here.
Posted 22nd October 2018 by Jane Williams
The Probiotics/Prebiotics Market
Interest in microbiota, specifically in human health and disease, has encouraged consumers to focus on digestive health, which has seen the probiotics and prebiotics market go from strength-to-strength.
As a result, the global probiotics and prebiotics market was valued at approximately USD 40.09 billion in 2017 and is expected to generate revenue of around USD 65.87 billion by end of 2024, growing at a compound annual growth rate of around 7.35% between 2018 and 2024. 
Posted 19th March 2018 by Jane Williams
Following on from his previous article about his research into the effects of everyday cosmetics on the skin microbiome, Kit Wallen-Russell delves deeper into the issues of the skin microbiome, by comparing the differences between biodiverse skin care and probiotic skin care.
Posted 27th December 2017 by Jane Williams
Defined health outcomes are increasingly being linked to prebiotic ingredients and supplements. For example, mounting evidence recently led the FDA to issue a qualified health claim regarding the ability of digestion resistant starch to reduce the risk of type 2 diabetes. With the direct annual cost of diabetes recently estimated to be $825B (1), the potential application of prebiotics to reduce disease risk is appealing from both health care and business investment perspectives.